Advertisement

PharmacoEconomics & Outcomes News

, Volume 844, Issue 1, pp 16–16 | Cite as

Glecaprevir/pibrentasvir dominates current DAAs for hep C in Japan

Clinical study
  • 1 Downloads

Reference

  1. Kawaguchi I, et al. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Advances in Therapy : 5 Dec 2019. Available from: URL: https://doi.org/10.1007/s12325-019-01166-3

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations